Trial
NCT05894447
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
NeoTX Therapeutics Ltd.
Condition
Urothelial Carcinoma
Intervention
Naptumomab Estafenatox
Why stopped
Insufficient funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-12